All In Biotech

Drug Trial Radar · NCT06863402

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

Nemtabrutinib and Pembrolizumab in Patients With Richter Transformation: A Phase II Study

Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Nov 15, 2026

Primary completion

Jun 1, 2029

Study completion Jun 1, 2030

Sponsor

Lead sponsor
Roswell Park Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial tests how well nemtabrutinib in combination with pembrolizumab works in treating patients with Richter transformation, diffuse large B-cell lymphoma subtype (RT-DLBCL). Nemtabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cells (a type of white blood cell) in cancers such as Richter transformation at abnormal levels. This may help keep cancer cells from growing and spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving nemtabrutinib in combination with pembrolizumab may kill more cancer cells in patients with RT-DLBCL.

Conditions

  • Richter Syndrome
  • Diffuse Large B-Cell Lymphoma
  • Chronic Lymphocytic Leukemia

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow biopsy

  • Computed TomographyProcedure

    Undergo PET/CT or CT

  • EchocardiographyProcedure

    Undergo ECHO

  • Multigated Acquisition ScanProcedure

    Undergo MUGA

  • NemtabrutinibDrug

    Given PO

  • PembrolizumabBiological

    Given IV

  • Positron Emission TomographyProcedure

    Undergo PET/CT

  • Questionnaire AdministrationOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall response rateTime frame: After 6 cycles (approximately 18 weeks) (1 cycle = 21 days)
  2. Quality of lifeTime frame: Up to 3 years after completion of study treatment
  3. Quality of life -PRO CTCAETime frame: Up to 3 years after completion of study treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Roswell Park Cancer Institute

    Buffalo, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.